Insider Selling: Travere Therapeutics (NASDAQ:TVTX) Insider Sells 2,174 Shares of Stock

Key Points

• Elizabeth Reed, a Travere insider, sold 2,174 shares on May 5 at an average price of $46.65 (≈$101,417) under a pre‑arranged Rule 10b5‑1 plan to cover tax withholding, cutting her position by about 1.99% to 107,287 shares (≈$5.0M).
• Travere reported Q1 EPS of $0.05 (vs. consensus -$0.24) and revenue of $127.2M (below the $136.2M estimate) with revenue up 55.6% YoY, which has prompted several analyst price‑target raises (e.g., TD Cowen to $60, Wells Fargo to $50) and an average target of $47.83.

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Elizabeth Reed sold 2,174 shares of the business's stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $46.65, for a total value of $101,417.10. Following the completion of the transaction, the insider directly owned 107,287 shares of the company's stock, valued at approximately $5,004,938.55. This trade represents a 1.99% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Travere Therapeutics Stock Performance

Shares of NASDAQ TVTX traded down $0.10 during midday trading on Wednesday, hitting $44.70. 2,390,035 shares of the company's stock traded hands, compared to its average volume of 2,890,153. Travere Therapeutics, Inc. has a 1 year low of $13.88 and a 1 year high of $48.61. The stock has a market capitalization of $4.16 billion, a price-to-earnings ratio of -194.33 and a beta of 1.13. The company has a debt-to-equity ratio of 3.16, a quick ratio of 2.70 and a current ratio of 3.13. The firm has a fifty day moving average of $32.59 and a 200 day moving average of $32.83.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its quarterly earnings results on Monday, May 4th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.24) by $0.29. The firm had revenue of $127.20 million during the quarter, compared to analyst estimates of $136.23 million. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The business's revenue for the quarter was up 55.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.47) EPS. On average, analysts forecast that Travere Therapeutics, Inc. will post -0.16 earnings per share for the current year.

Key Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target from $45 to $60 and kept a "buy" rating, implying meaningful upside vs. current levels — a bullish signal from a major sell‑side shop. TD Cowen price target raise
• Positive Sentiment: Wells Fargo upgraded its target to $50 and assigned an "overweight" rating, another near‑term positive catalyst supporting higher valuation expectations. Wells Fargo price target raise
• Neutral Sentiment: HC Wainwright reiterated a "Buy" and $57 target but trimmed FY2027–FY2030 EPS forecasts slightly (e.g., FY2027 cut from $0.71 to $0.60; FY2030 to $4.59 from $4.61). The firm still models substantial multi‑year growth, so this is more of a modest forecast tweak than a change in conviction. HC Wainwright note
• Neutral Sentiment: Earnings call transcript for Q1 2026 is available — recall Travere reported a year‑over‑year revenue gain and an EPS beat in the quarter, which helped underpin recent analyst upgrades. Review the transcript for management commentary on sparsentan commercialization and margin trajectory. Q1 2026 earnings transcript
• Negative Sentiment: Director Roy Baynes sold 9,750 shares (about $431k at the sale price) under a pre‑arranged Rule 10b5‑1 plan. Insider sales can be perceived negatively by the market despite the trading plan disclosure; monitor for any further insider activity. Insider sale filing

Institutional Trading of Travere Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in Travere Therapeutics by 10.3% in the third quarter. Vanguard Group Inc. now owns 6,613,368 shares of the company's stock worth $158,059,000 after purchasing an additional 619,085 shares during the period. State Street Corp increased its stake in Travere Therapeutics by 47.8% in the fourth quarter. State Street Corp now owns 4,756,666 shares of the company's stock worth $181,752,000 after purchasing an additional 1,538,827 shares during the period. Perceptive Advisors LLC increased its stake in Travere Therapeutics by 12.7% in the fourth quarter. Perceptive Advisors LLC now owns 4,278,180 shares of the company's stock worth $163,469,000 after purchasing an additional 483,565 shares during the period. Adage Capital Partners GP L.L.C. increased its stake in Travere Therapeutics by 27.4% in the second quarter. Adage Capital Partners GP L.L.C. now owns 2,784,000 shares of the company's stock worth $41,203,000 after purchasing an additional 599,102 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Travere Therapeutics by 28.2% in the fourth quarter. Renaissance Technologies LLC now owns 2,246,779 shares of the company's stock worth $85,849,000 after purchasing an additional 494,665 shares during the period.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on TVTX shares. JPMorgan Chase & Co. lowered their target price on Travere Therapeutics from $44.00 to $41.00 and set an "overweight" rating for the company in a research report on Wednesday, March 25th. TD Cowen increased their price target on Travere Therapeutics from $45.00 to $60.00 and gave the company a "buy" rating in a report on Tuesday. Canaccord Genuity Group increased their price target on Travere Therapeutics from $47.00 to $56.00 and gave the company a "buy" rating in a report on Tuesday, April 14th. Guggenheim increased their price target on Travere Therapeutics from $54.00 to $56.00 and gave the company a "buy" rating in a report on Friday, April 24th. Finally, HC Wainwright increased their price target on Travere Therapeutics from $47.00 to $57.00 and gave the company a "buy" rating in a report on Tuesday. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Travere Therapeutics has an average rating of "Moderate Buy" and an average price target of $47.83.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.